The study of programmed death ligand-1 (PD-L1) expression and programmed death-1 (PD-1)-positive tumor-infiltrating lymphocytes became a further line of research, quickly considering the use some immunological drugs able to inhibit PD-1/PD-L1 pathway. The gene discussed is CD274; the disease is neoplasm.